Report Detail
Global Drug Repositioning Supply, Demand and Key Producers, 2026-2032
- RnM4667122 |
- 22 January, 2026 |
- Global |
- 130 Pages |
- GIR |
- Service & Software
The global Drug Repositioning market size is expected to reach $ 43510 million by 2032, rising at a market growth of 4.6% CAGR during the forecast period (2026-2032).
Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
The drug repositioning market is driven by the growing demand for cost-effective and time-saving drug development strategies. Traditional drug discovery can take over a decade and cost billions of dollars, with a high risk of failure during clinical trials. Repositioning, on the other hand, allows pharmaceutical companies to repurpose known drugs with existing safety and pharmacokinetic profiles, thereby accelerating time to market and reducing development risk. This approach is especially appealing for rare diseases, cancer, and neurodegenerative disorders where treatment options are limited. Additionally, advances in data mining, artificial intelligence, and systems biology have improved the ability to identify new drug-disease relationships, fueling further interest. Regulatory agencies such as the FDA and EMA also support repositioning by offering faster review pathways and incentives for orphan indications, making this strategy increasingly viable from a business perspective.
Despite its advantages, the drug repositioning market faces several challenges. One of the major issues is intellectual property protection—many repositioned drugs are off-patent, making it difficult for companies to secure exclusivity and justify investment. In cases where patent life can be extended through new formulations or uses, legal and regulatory hurdles still exist. Another challenge lies in clinical validation; while safety data may already be available, proving efficacy for a new indication still requires substantial clinical trial investment. Moreover, the lack of centralized, standardized databases for repositioning candidates limits discovery efficiency. The fragmented nature of available data—spread across academic publications, clinical trial registries, and real-world evidence—makes it hard to integrate and analyze comprehensively. Finally, collaboration between industry and academia, which is crucial for repositioning, is often hindered by misaligned goals and timelines.
This report studies the global Drug Repositioning demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Drug Repositioning, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Drug Repositioning that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Drug Repositioning total market, 2021-2032, (USD Million)
Global Drug Repositioning total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Drug Repositioning total market, key domestic companies, and share, (USD Million)
Global Drug Repositioning revenue by player, revenue and market share 2021-2026, (USD Million)
Global Drug Repositioning total market by Type, CAGR, 2021-2032, (USD Million)
Global Drug Repositioning total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Drug Repositioning market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, Bausch Health, GSK, ChemRar Group, Glenmark, Fujifilm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Drug Repositioning market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Drug Repositioning Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Drug Repositioning Market, Segmentation by Type:
Generic Drugs
Clinical Trial Failed Drugs
Global Drug Repositioning Market, Segmentation by Application:
Cardiovascular Diseases
Mental Illness
Cancer
Others
Companies Profiled:
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Key Questions Answered
1. How big is the global Drug Repositioning market?
2. What is the demand of the global Drug Repositioning market?
3. What is the year over year growth of the global Drug Repositioning market?
4. What is the total value of the global Drug Repositioning market?
5. Who are the Major Players in the global Drug Repositioning market?
6. What are the growth factors driving the market demand?
1 Supply Summary
- 1.1 Drug Repositioning Introduction
- 1.2 World Drug Repositioning Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Drug Repositioning Total Market by Region (by Headquarter Location)
- 1.3.1 World Drug Repositioning Market Size by Region (2021-2032), (by Headquarter Location)
- 1.3.2 United States Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.3 China Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.4 Europe Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.5 Japan Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.6 South Korea Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.7 ASEAN Based Company Drug Repositioning Revenue (2021-2032)
- 1.3.8 India Based Company Drug Repositioning Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
- 1.4.1 Drug Repositioning Market Drivers
- 1.4.2 Factors Affecting Demand
- 1.4.3 Major Market Trends
2 Demand Summary
- 2.1 World Drug Repositioning Consumption Value (2021-2032)
- 2.2 World Drug Repositioning Consumption Value by Region
- 2.2.1 World Drug Repositioning Consumption Value by Region (2021-2026)
- 2.2.2 World Drug Repositioning Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Drug Repositioning Consumption Value (2021-2032)
- 2.4 China Drug Repositioning Consumption Value (2021-2032)
- 2.5 Europe Drug Repositioning Consumption Value (2021-2032)
- 2.6 Japan Drug Repositioning Consumption Value (2021-2032)
- 2.7 South Korea Drug Repositioning Consumption Value (2021-2032)
- 2.8 ASEAN Drug Repositioning Consumption Value (2021-2032)
- 2.9 India Drug Repositioning Consumption Value (2021-2032)
3 World Drug Repositioning Companies Competitive Analysis
- 3.1 World Drug Repositioning Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
- 3.2.1 Global Drug Repositioning Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for Drug Repositioning in 2025
- 3.2.3 Global Concentration Ratios (CR8) for Drug Repositioning in 2025
- 3.3 Drug Repositioning Company Evaluation Quadrant
- 3.4 Drug Repositioning Market: Overall Company Footprint Analysis
- 3.4.1 Drug Repositioning Market: Region Footprint
- 3.4.2 Drug Repositioning Market: Company Product Type Footprint
- 3.4.3 Drug Repositioning Market: Company Product Application Footprint
- 3.5 Competitive Environment
- 3.5.1 Historical Structure of the Industry
- 3.5.2 Barriers of Market Entry
- 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity
4 United States VS China VS Rest of World (by Headquarter Location)
- 4.1 United States VS China: Drug Repositioning Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: Drug Repositioning Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
- 4.1.2 United States VS China: Drug Repositioning Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: Drug Repositioning Consumption Value Comparison
- 4.2.1 United States VS China: Drug Repositioning Consumption Value Comparison (2021 & 2025 & 2032)
- 4.2.2 United States VS China: Drug Repositioning Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based Drug Repositioning Companies and Market Share, 2021-2026
- 4.3.1 United States Based Drug Repositioning Companies, Headquarters (States, Country)
- 4.3.2 United States Based Companies Drug Repositioning Revenue, (2021-2026)
- 4.4 China Based Companies Drug Repositioning Revenue and Market Share, 2021-2026
- 4.4.1 China Based Drug Repositioning Companies, Company Headquarters (Province, Country)
- 4.4.2 China Based Companies Drug Repositioning Revenue, (2021-2026)
- 4.5 Rest of World Based Drug Repositioning Companies and Market Share, 2021-2026
- 4.5.1 Rest of World Based Drug Repositioning Companies, Headquarters (Province, Country)
- 4.5.2 Rest of World Based Companies Drug Repositioning Revenue (2021-2026)
5 Market Analysis by Type
- 5.1 World Drug Repositioning Market Size Overview by Type: 2021 VS 2025 VS 2032
- 5.2 Segment Introduction by Type
- 5.2.1 Generic Drugs
- 5.2.2 Clinical Trial Failed Drugs
- 5.3 Market Segment by Type
- 5.3.1 World Drug Repositioning Market Size by Type (2021-2026)
- 5.3.2 World Drug Repositioning Market Size by Type (2027-2032)
- 5.3.3 World Drug Repositioning Market Size Market Share by Type (2027-2032)
6 Market Analysis by Application
- 6.1 World Drug Repositioning Market Size Overview by Application: 2021 VS 2025 VS 2032
- 6.2 Segment Introduction by Application
- 6.2.1 Cardiovascular Diseases
- 6.2.2 Mental Illness
- 6.2.3 Cancer
- 6.2.4 Others
- 6.3 Market Segment by Application
- 6.3.1 World Drug Repositioning Market Size by Application (2021-2026)
- 6.3.2 World Drug Repositioning Market Size by Application (2027-2032)
- 6.3.3 World Drug Repositioning Market Size Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Teva
- 7.1.1 Teva Details
- 7.1.2 Teva Major Business
- 7.1.3 Teva Drug Repositioning Product and Services
- 7.1.4 Teva Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.1.5 Teva Recent Developments/Updates
- 7.1.6 Teva Competitive Strengths & Weaknesses
- 7.2 Novartis
- 7.2.1 Novartis Details
- 7.2.2 Novartis Major Business
- 7.2.3 Novartis Drug Repositioning Product and Services
- 7.2.4 Novartis Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.2.5 Novartis Recent Developments/Updates
- 7.2.6 Novartis Competitive Strengths & Weaknesses
- 7.3 Mylan
- 7.3.1 Mylan Details
- 7.3.2 Mylan Major Business
- 7.3.3 Mylan Drug Repositioning Product and Services
- 7.3.4 Mylan Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.3.5 Mylan Recent Developments/Updates
- 7.3.6 Mylan Competitive Strengths & Weaknesses
- 7.4 Johnson & Johnson
- 7.4.1 Johnson & Johnson Details
- 7.4.2 Johnson & Johnson Major Business
- 7.4.3 Johnson & Johnson Drug Repositioning Product and Services
- 7.4.4 Johnson & Johnson Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.4.5 Johnson & Johnson Recent Developments/Updates
- 7.4.6 Johnson & Johnson Competitive Strengths & Weaknesses
- 7.5 Pfizer
- 7.5.1 Pfizer Details
- 7.5.2 Pfizer Major Business
- 7.5.3 Pfizer Drug Repositioning Product and Services
- 7.5.4 Pfizer Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.5.5 Pfizer Recent Developments/Updates
- 7.5.6 Pfizer Competitive Strengths & Weaknesses
- 7.6 Bausch Health
- 7.6.1 Bausch Health Details
- 7.6.2 Bausch Health Major Business
- 7.6.3 Bausch Health Drug Repositioning Product and Services
- 7.6.4 Bausch Health Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.6.5 Bausch Health Recent Developments/Updates
- 7.6.6 Bausch Health Competitive Strengths & Weaknesses
- 7.7 GSK
- 7.7.1 GSK Details
- 7.7.2 GSK Major Business
- 7.7.3 GSK Drug Repositioning Product and Services
- 7.7.4 GSK Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.7.5 GSK Recent Developments/Updates
- 7.7.6 GSK Competitive Strengths & Weaknesses
- 7.8 ChemRar Group
- 7.8.1 ChemRar Group Details
- 7.8.2 ChemRar Group Major Business
- 7.8.3 ChemRar Group Drug Repositioning Product and Services
- 7.8.4 ChemRar Group Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.8.5 ChemRar Group Recent Developments/Updates
- 7.8.6 ChemRar Group Competitive Strengths & Weaknesses
- 7.9 Glenmark
- 7.9.1 Glenmark Details
- 7.9.2 Glenmark Major Business
- 7.9.3 Glenmark Drug Repositioning Product and Services
- 7.9.4 Glenmark Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.9.5 Glenmark Recent Developments/Updates
- 7.9.6 Glenmark Competitive Strengths & Weaknesses
- 7.10 Fujifilm
- 7.10.1 Fujifilm Details
- 7.10.2 Fujifilm Major Business
- 7.10.3 Fujifilm Drug Repositioning Product and Services
- 7.10.4 Fujifilm Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.10.5 Fujifilm Recent Developments/Updates
- 7.10.6 Fujifilm Competitive Strengths & Weaknesses
- 7.11 Dr. Reddy
- 7.11.1 Dr. Reddy Details
- 7.11.2 Dr. Reddy Major Business
- 7.11.3 Dr. Reddy Drug Repositioning Product and Services
- 7.11.4 Dr. Reddy Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.11.5 Dr. Reddy Recent Developments/Updates
- 7.11.6 Dr. Reddy Competitive Strengths & Weaknesses
- 7.12 R-Pharma
- 7.12.1 R-Pharma Details
- 7.12.2 R-Pharma Major Business
- 7.12.3 R-Pharma Drug Repositioning Product and Services
- 7.12.4 R-Pharma Drug Repositioning Revenue, Gross Margin and Market Share (2021-2026)
- 7.12.5 R-Pharma Recent Developments/Updates
- 7.12.6 R-Pharma Competitive Strengths & Weaknesses
8 Industry Chain Analysis
- 8.1 Drug Repositioning Industry Chain
- 8.2 Drug Repositioning Upstream Analysis
- 8.3 Drug Repositioning Midstream Analysis
- 8.4 Drug Repositioning Downstream Analysis
9 Research Findings and Conclusion
10 Appendix
- 10.1 Methodology
- 10.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Drug Repositioning. Industry analysis & Market Report on Drug Repositioning is a syndicated market report, published as Global Drug Repositioning Supply, Demand and Key Producers, 2026-2032. It is complete Research Study and Industry Analysis of Drug Repositioning market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
